期刊文献+

异氟烷对小鼠星型胶质细胞Sirt1和MAO-A基因表达的影响

Effect of Isoflurane on the Expression of Sirt1/MAO-A in Cultured Astrocytes
原文传递
导出
摘要 目的:探讨异氟烷对小鼠星形胶质细胞Sirt1和MAO-A基因表达的影响。方法:给予体外培养的新生小鼠原代星形胶质细胞不同浓度异氟烷处理,实验分为对照组和异氟烷处理组(0.5ISO、1.0ISO、1.5ISO),其中异氟烷组细胞分别给予0.5 MAC、1.0MAC和1.5 MAC三个浓度的异氟烷处理2小时,对照组给予O_2处理2小时,然后提取细胞RNA和蛋白检测Sirt1和MAO-A的mRNA和蛋白表达变化。结果:与对照组相比,异氟烷下调小鼠星形胶质细胞的Sirt1和MAO-A mRNA和蛋白水平,异氟烷浓度越大下调越明显。结论:异氟烷可抑制小鼠星形胶质细胞的Sirt1和MAO-A基因表达。 Objective:To explore the effect of isoflurane on the expression of Sirtl/MAO-A of Astrocytes.Methods:Cultured astrocytes from newborn mice were divided into control and isoflurane groups:control group was treated with O2 for 2 hours and isoflurane treatment groups (0.5ISO,1.0ISO,1.5ISO) were treated with 0.5 MAC,1.0 MAC and 1.5 MAC of isoflurane for 2 hours respectively.Then total RNA and protein was extracted from cells and the mRNA and protein levels of Sirtl and MAO-A were measured by Real-time PCR and Western blot respectively.Results:(1) Compared with the control,Isoflurane significantly down-regulated the mRNA as well as protein levels of Sirtl and MAO-A in the cultured astrocytes;(2) The effect of isoflurane revealed a dose effect---compared with 0.5ISO group,cells treated with 1.0MAC and 1.5 MAC of isoflurane suffered more influence.Conclusion:Isoflurane exposure suppressed the expression of Sirt1/MAO-A of astrocytes from newborn mice brain,which is important for the isoflurane narcotherapy in depressive.
出处 《现代生物医学进展》 CAS 2017年第15期2817-2820,共4页 Progress in Modern Biomedicine
基金 国家自然科学基金项目(81401109 81571309)
关键词 异氟烷 星形胶质细胞 SIRT1 MAO—A Isoflurane Astrocytes MAO-A
  • 相关文献

参考文献3

二级参考文献42

  • 1Mullya VV, Heinonen EH, Vuorinrn JA, et at. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease [J]. Acta Neurol Scand, 1995, 91:177-182.
  • 2Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future[J ]. Neurotoxicology, 2004, 25 (12): 215-221.
  • 3Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel secondgeneration propergylamine for the treatment of Parkinson's dis- ease[J]. J Clin Pharmacol, 2005, 45(12): 878-894.
  • 4Moussa BH, Youdim MBH, Peter F. A review oft he mechanisms and role ofmonoamine oxidase inhibitors in Parkinson's disease [J]. Neu- rology, 2004, 63 (7 Suppl 2): S322 35.
  • 5Ito D, Amano T, Sato H, et al. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease [J]. J Neurol, 2001, 248(23): 33-34.
  • 6Olivier Rascol, Cheryl J Fitzer-Attas, Robert Hanser. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecifi ed and post-boc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes [M]. Lancet Neurol, 2011, 10(33): 415-23.
  • 7C. Warren Olanow, Robert A. Hauser, Joseph Jankovic. A Random- ized, Double-Blind, Placebo-Controlled, Delayed Start Study to As- sess Rasagiline as a Disease Modifying Therapy in Parkinson's Dis- ease (The ADAGIO Study): Rationale, Design, and Baseline Charac- teristics[M]. Movement Disorders, 2008, 23 (15): 2194-2201.
  • 8Wakako Maruyama o Makoto Naoi. "70th Birthday Professor Riederer" Induction ofglial cell linederived and brain-derived neurotrophie fac- tors by rasagiline and (2) deprenyl: a way to a disease-modifying ther- apy [J]. Journal of Neural Transmission, published online 15 August 2012.
  • 9Donnan PT, Steinke DT, Stubbings C, et al. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study [J]. Neurology, 2000, 55(34): 1785-1789.
  • 10Henkel V, Mergl R, Allgaier AK. Treatment of depression with atypi- cal features: a meta-analytic approach [J]. Psychiatry Res, 2006, 141 (1): 89-101.

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部